Skip to main content

Table 3 Association between metformin plus sodium-glucose transporter 2 inhibitors and metformin plus insulin and study outcomes after propensity score matching

From: Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Outcomes

Treatment groups

McNemar test

 

Metformin + SGLT-2i (n = 34)

Other GLD (n = 34)

p value

 

In-hospital deaths

6 (17.6%)

10 (29.4%)

0.391

1.000

ICU admission, mechanical ventilation, or in-hospital death

10 (29.4%)

11 (32.4%)

0.987

0.965

In-hospital complications

19 (55.9%)

22 (64.7%)

0.620

0.201

Long-time hospital stay

6 (17.6%)

4 (11.8%)

0.732

0.838

 

Metformin + insulin (n = 67)

Other GLD (n = 67)

p value

 

In-hospital deaths

24 (35.8%)

23 (34.3%)

1.000

0.521

ICU admission, mechanical ventilation, or in-hospital death

46 (68.7%)

36 (53.7%)

0.112

0.111

In-hospital complications

44 (65.7%)

36 (53.7%)

0.218

0.480

Long-time hospital stay

15 (22.4%)

13 (19.4%)

0.832

0.870

  1. Data are shown as absolute values and percentages. Values were considered to be statistically significant when p < 0.05
  2. GLD glucose-lowering drugs, ICU intensive care unit, SGLT-2i sodium-glucose transporter 2 inhibitors